Ipamorelin vs Hexarelin: Research Comparison | Peptide Intel Hub

Ipamorelin is a selective pentapeptide agonist at the growth-hormone-secretagogue receptor (GHS-R1a / ghrelin receptor), engineered for clean GH pharmacology without measurable effect on cortisol, prolactin or appetite in published research.

Hexarelin is a hexapeptide ghrelin-receptor agonist derived from GHRP-6 — potent at driving GH release but with measurable cortisol and prolactin effects at research doses, and additional cardiovascular-axis effects described in the published literature.

Both compounds act at the GHS-R1a receptor. Ipamorelin's selectivity is the key differentiator — it engages the growth-hormone axis without the cortisol / prolactin off-targets characteristic of first-generation GHRPs.

Hexarelin shows stronger GH-release potency at matched doses but the off-target cortisol and prolactin activity make it a less clean tool for isolating growth-hormone-axis signalling in research designs.

Ipamorelin has a short pharmacokinetic half-life (roughly two hours) and is typically used at once- or twice-daily research cadence.

Hexarelin has a similarly short native half-life and is used at once- to twice-daily cadence in research protocols; the higher potency per dose is offset by the wider off-target profile.

Ipamorelin is the standard GHRP arm in growth-hormone secretagogue research panels, particularly when paired with a GHRH analogue (CJC-1295 or tesamorelin) to combine both arms of the GH-release axis.

Hexarelin is used in cardiovascular-axis research where the additional off-target effects are part of the experimental design, and in comparator studies isolating the selectivity contribution of ipamorelin above the older-generation GHRP baseline.

Both Ipamorelin and Hexarelin should only be sourced from suppliers that use independent third-party verification — Janoshik Analytical is the default verifier, with orthogonal independent laboratories used when batch chemistry calls for confirmation by a second method. Minimum release specification is ≥99.0% HPLC main-peak purity with matching mass-spectrometry molecular weight and water content within the published specification for the compound.

Batch COAs for both compounds should be published by the supplier so a researcher can audit the analytical detail. The /trust/how-to-read-a-coa reference walks through every field on a modern COA.

Both compounds ship lyophilised under nitrogen. Hold the unopened vial at 2–8 °C; freeze at −20 °C for long-term storage. Reconstitution with bacteriostatic water (0.9% benzyl alcohol) supports a two-month (60-day) in-use stability window under refrigeration for both compounds.

Aliquot before any freeze. The single most common cause of measurable potency loss in research peptides is repeat freeze-thaw cycling — both Ipamorelin and Hexarelin benefit from single-thaw aliquot workflows. Vortex gently, never shake aggressively, and keep reconstituted vials away from direct light. The /research/compound-storage-guide reference covers the per-compound stability windows in detail.

Researchers choose ipamorelin when the protocol requires clean ghrelin-axis GH release without cortisol / prolactin off-targets, or when pairing with a GHRH analogue for combined-axis growth-hormone research. Researchers choose hexarelin when the protocol targets the older-generation GHRP pharmacology directly, when the additional cardiovascular-axis effects are relevant, or when comparator studies isolate ipamorelin's selectivity advantage against a first-generation GHRP baseline.

For multi-compound comparator studies, reputable suppliers can often reserve matched-batch inventory of both Ipamorelin and Hexarelin against a project timeline so the experimental panel is sourced under a single analytical specification window.

Ipamorelin is characterized as a new potent growth hormone (GH) secretagogue, identified as a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) (PMID 9849822). It exhibits high GH releasing potency and efficacy both in vitro and in vivo (PMID 9849822). In laboratory settings, ipamorelin effectively releases GH from primary rat pituitary cells, demonstrating similar potency and efficacy to GHRP-6 (PMID 9849822). Specifically, its half maximal effective concentration (EC50) was 1.3+/-0.4 nmol/l, and its maximal efficacy (Emax) reached 85+/-5% (PMID 9849822). This activity profile suggests it stimulates GH release via a GHRP-like receptor, a mechanism shared with GHRP-6 (PMID 9849822). The specificity of ipamorelin for GH release makes it a candidate for clinical development (PMID 9849822).

Pharmacological investigations in animals have further elucidated ipamorelin's effects. In pentobarbital-anaesthetized rats, ipamorelin released GH with an efficacy comparable to GHRP-6, with an ED50 of 80+/-42 nmol/kg (PMID 9849822). Studies in conscious swine revealed an ED50 of 2.3+/-0.03 nmol/kg and an Emax of 65+/-0.2 ng GH/ml plasma for GH release, closely mirroring GHRP-6 (PMID 9849822). A significant distinction of ipamorelin lies in its specificity: in swine, unlike GHRP-6 and GHRP-2, ipamorelin did not significantly affect plasma levels of FSH, LH, PRL, ACTH, or cortisol, even at doses over 200-fold higher than its ED50 for GH release (PMID 9849822). This selective GH-releasing property, similar to GHRH, positions ipamorelin as the first GHRP-receptor agonist with such selectivity (PMID 9849822).

Beyond GH release, ipamorelin has shown other physiological effects in animal models. In adult female rats, ipamorelin dose-dependently increased longitudinal bone growth rate (LGR) from 42 µm/day in the control group to 52 µm/day at the highest dose (PMID 10373343). It also led to a pronounced and dose-dependent increase in body weight gain in these rats (PMID 10373343). Furthermore, a study in tilapia (Oreochromis mossambicus) demonstrated that ipamorelin acetate, a ghrelin agonist, significantly increased food intake and enhanced the development of germ cells during meiosis-I, potentially mediated by stimulating 11-ketotestosterone and androgen receptors at the testicular level and luteinizing hormone at the pituitary level (PMID 38996787). In ferrets, ipamorelin administered intraperitoneally inhibited cisplatin-induced weight loss during the delayed phase (48-72 hours) by approximately 24% (PMID 39043357). Pharmacokinetic evaluation in male rats indicated that ipamorelin had a systemic plasma clearance five-fold lower than GHRP-6 and was primarily excreted in the urine, with an estimated bioavailability of approximately 20% after intranasal application (PMID 9879640).

Hexarelin is recognized as a synthetic growth hormone-releasing peptide that binds to and activates the growth hormone secretagogue receptor (GHSR) in the brain, similar to its natural analogue, ghrelin (PMID 25278975). Unlike ghrelin, hexarelin is described as chemically more stable and functionally more potent (PMID 25278975). Early research highlighted that GHRPs like hexarelin exhibit strong, dose-dependent, and reproducible GH-releasing activity, along with significant prolactin (PRL) and adrenocorticotropic hormone (ACTH)/cortisol-releasing effects (PMID 10790589). Specific GHRP receptor binding has been observed in various peripheral tissues, including the heart, adrenal, ovary, testis, lung, and skeletal muscle (PMID 10790589). A notable finding is the specific binding of radiolabeled Tyr-Ala-hexarelin in the human cardiovascular system, with the highest binding levels detected in the ventricles (PMID 10790589). This binding is inhibited by hexarelin, GHRP-6, GHRP-1, and GHRP-2 (PMID 10790589).

Beyond its role as a GHSR ligand, hexarelin has demonstrated cardioprotective effects. In an in-vitro study on H9c2 myocytes (fetal cardiomyocyte-derived cell line), hexarelin showed anti-apoptotic activity (PMID 10790589). Furthermore, the non-GHSR CD36 has been identified as a specific cardiac receptor for hexarelin, mediating its cardioprotective effects (PMID 25278975). In rats subjected to ischemia/reperfusion-induced acute kidney injury (AKI), pretreatment with hexarelin (100 µg/kg/d for 7 days) mitigated post-ischemic kidney pathological changes, improved renal function, and inhibited apoptosis (PMID 37710348). This was achieved through the downregulation of apoptosis-related genes like Caspase-3, Bax, and Bad, and upregulation of Bcl-2 (PMID 37710348). In vitro, hexarelin also reduced cell apoptosis in post-hypoxia/reoxygenation HK-2 cells, with molecular docking suggesting a strong binding affinity between hexarelin and MDM2, a negative regulator of p53 (PMID 37710348).

Hexarelin's protective actions extend to other organ systems and cellular processes. In a mouse model of elastase-induced abdominal aortic aneurysm (AAA), hexarelin administration (200 µg/kg twice daily) decreased infrarenal aorta diameter, improved elastin degradation, rescued smooth muscle cell contractile phenotype, inhibited inflammatory cell infiltration, and suppressed NF-κB signaling (PMID 34856183). In a murine model of HCl-induced acute respiratory distress syndrome (ARDS), hexarelin (320 µg/kg, ip) significantly improved lung compliance, reduced immune cells in bronchoalveolar lavage, and led to less pulmonary collagen deposition after 14 days, indicating an inhibition of early inflammatory response and blunting of lung remodeling (PMID 34871336). In H9C2 cardiomyocytes, hexarelin suppressed angiotensin-II induced hypertrophy, oxidative stress, and apoptosis by enhancing autophagy, a process linked to the suppression of the mTOR signaling pathway (PMID 31526442). Moreover, in ApoE-/- mice, hexarelin (100 µg/kg s.c., q.d. for 3 months) attenuated atherosclerosis progression by modulating circulatory lipids, decreasing serum TC, TG, and LDL-c, increasing HDL-c, and inhibiting macrophage ox-LDL uptake via suppressing the LOX-1-NF-κB signaling pathway (PMID 31386895). Its neuroprotective and anti-apoptotic effects were also observed in Neuro-2A cells, where hexarelin antagonized hydrogen peroxide-induced damage, improved cell viability, and modulated MAPK and Akt pathways (PMID 34066741). Hexarelin has been reported to regulate peroxisome proliferator-activated receptor gamma (PPAR-γ) in macrophages and adipocytes, a key regulator of adipogenesis, lipid metabolism, and insulin sensitization (PMID 25645463).

A primary distinguishing feature between ipamorelin and hexarelin, highlighted in early research, is their specificity concerning the release of hormones beyond growth hormone (GH). Ipamorelin was identified as the first GHRP-receptor agonist to demonstrate a selectivity for GH release similar to that displayed by GHRH (PMID 9849822). In conscious swine studies, ipamorelin did not significantly affect plasma levels of FSH, LH, PRL, ACTH, or cortisol, even at doses more than 200-fold higher than its effective dose for GH release (PMID 9849822). This contrasts with GHRP-6 and GHRP-2, which resulted in increased plasma levels of ACTH and cortisol in the same swine model (PMID 9849822).

Conversely, hexarelin, as part of the broader GH-releasing peptide (GHRP) family, has been noted to exhibit significant PRL- and ACTH/cortisol-releasing effects in addition to its strong, dose-dependent GH-releasing activity (PMID 10790589). While both peptides bind to and activate the GHSR (PMID 25278975, PMID 9849822), hexarelin's influence on these additional hormones indicates a broader physiological impact on the neuroendocrine system compared to the more selective action attributed to ipamorelin (PMID 10790589, PMID 9849822). This difference in specificity is a critical consideration when evaluating their respective pharmacological profiles.

Both ipamorelin and hexarelin are categorized within a group of therapeutic peptides that have garnered interest in orthopedics and sports medicine, largely due to their potential to modulate molecular signaling networks crucial for tissue regeneration, inflammation resolution, and neuromuscular recovery (PMID 41490200). Ipamorelin, specifically, is mentioned as a growth hormone secretagogue that activates IGF-1 signaling and satellite cell repair pathways (PMID 41490200). In preclinical animal models, ipamorelin has shown promising results. For instance, CJC-1295 combined with ipamorelin significantly improved maximum tetanic tension in murine models with glucocorticoid-induced muscle loss (PMID 41476424). Additionally, ipamorelin dose-dependently increased longitudinal bone growth rate (LGR) and body weight gain in adult female rats (PMID 10373343). These findings suggest a role for ipamorelin in bone and muscle health in animal contexts.

However, the translation of these preclinical findings to human orthopedic applications remains largely unvalidated (PMID 41476424, PMID 42578445). While the peptide supplement market for musculoskeletal recovery and enhancement is growing, driven by marketing claims, there is a noted absence of efficacy or safety data for many emerging peptides, including ipamorelin, in human trials (PMID 42578445). A comprehensive literature search highlighted that 67% of identified publications on peptides like ipamorelin utilized preclinical animal models, with human clinical studies being limited and often lacking robust controls or rigorous study designs (PMID 42578445). Despite promising effects on tendon, muscle, bone, and ligament healing in animal models, the claimed benefits of ipamorelin for musculoskeletal recovery and performance are unsubstantiated by current human trials (PMID 42578445).

Hexarelin's direct applications in orthopedics are less explicitly detailed in the provided abstracts compared to ipamorelin. However, its broader cardioprotective effects and anti-inflammatory properties (PMID 34856183, PMID 34871336) suggest potential indirect relevance to musculoskeletal health, given that inflammation is a key aspect of injury and recovery. The overarching theme for both peptides in this domain is a significant gap between promising animal research and validated human clinical evidence (PMID 41476424, PMID 42578445, PMID 41966639).

Hexarelin has a well-documented array of cardiovascular and metabolic effects. It is known to possess direct cardiotropic actions and protective effects against ischemia-induced myocardial damage in aged and GH deficient rats (PMID 10790589). Research indicates that hexarelin can exert cardioprotective effects through a specific cardiac receptor, CD36, independent of GHSR (PMID 25278975). In human cardiovascular tissue, specific binding of hexarelin has been observed, with high levels in ventricles (PMID 10790589). Further studies have shown hexarelin attenuates atherosclerosis in ApoE-/- mice by modulating circulatory lipids and inhibiting macrophage ox-LDL uptake via the LOX-1-NF-κB signaling pathway (PMID 31386895). It also protects cardiac H9C2 cells from angiotensin II-induced hypertrophy by regulating autophagy through the suppression of the mTOR signaling pathway (PMID 31526442). Moreover, hexarelin has been reported to regulate peroxisome proliferator-activated receptor gamma (PPAR-γ) in macrophages and adipocytes, which is important for adipogenesis, lipid metabolism, and insulin sensitization (PMID 25645463). Its potential in diabetes and diabetes-associated heart diseases, including beta cell protection and regeneration, is also under review (PMID 25645463).

While ipamorelin is primarily recognized for its selective GH-releasing properties (PMID 9849822), its direct cardiovascular or metabolic impacts are less comprehensively detailed in the provided abstracts compared to hexarelin. However, as a growth hormone secretagogue, ipamorelin activates IGF-1 signaling (PMID 41490200). Disruptions in growth hormone axis and insulin-like growth factor (GH/IGF) are relevant to aging and longevity (PMID 25045704). Therefore, its modulation of the GH/IGF axis could indirectly influence metabolic processes. It is important to note the significant findings regarding hexarelin's specific binding to human cardiovascular tissue, suggesting a direct role independent of its GH-releasing activity (PMID 10790589).

Both ipamorelin and hexarelin belong to a category of peptides where there's a significant disparity between preclinical promise and validated human clinical evidence, raising concerns about their safety and regulatory status, especially in non-medical contexts. While some peptide drugs undergo rigorous approval processes, a 'gray market' of unapproved compounds, including ipamorelin, has emerged (PMID 41966639). Many unapproved peptides demonstrate favorable outcomes in animal models, but rigorous human safety data are scarce, and there is potential for serious harm to patients (PMID 41966639). The peptide supplement market for recovery and performance, which includes ipamorelin, often lacks efficacy or safety data, despite perceptions of low risk (PMID 42578445).

The use of peptides like ipamorelin in sports and bodybuilding is increasing, marketed for muscle growth, fat metabolism, and recovery (PMID 41880199). However, clinical evidence supporting such use is limited, with most studies examining therapeutic applications under controlled dosing regimens, not the supraphysiological or combined protocols common in bodybuilding (PMID 41880199). Emerging data highlight potential risks, such as cardiovascular strain, insulin resistance, dyslipidemia, and psychiatric instability (PMID 41880199). The unregulated supply chain further exacerbates these dangers, with products often mislabeled or contaminated (PMID 41880199). Regulatory bodies like the World Anti-Doping Agency (WADA) are expanding detection technologies, but challenges remain due to peptides' structural similarity to endogenous hormones and short half-lives (PMID 41880199).

For hexarelin, while preclinical studies underscore its protective effects in various organ injuries (PMID 37710348, PMID 34856183, PMID 34871336, PMID 31526442, PMID 31386895, PMID 34066741), the abstracts do not specifically detail its regulatory status or safety in widespread human use, particularly outside of controlled research settings. However, given its classification as a synthetic growth hormone-releasing peptide and its functional potency compared to ghrelin (PMID 25278975), it likely falls under similar regulatory scrutiny and concerns regarding unapproved use as other GHRPs. Both peptides require rigorous validation through well-designed clinical trials to establish safety and efficacy for human health applications (PMID 42021992, PMID 42123471).

Across the body of research, a recurring theme for both ipamorelin and hexarelin is the significant discrepancy between promising preclinical findings and a current scarcity of robust human clinical evidence. For ipamorelin, in-vitro and animal studies have consistently demonstrated its potent and selective GH-releasing activity, along with effects on longitudinal bone growth and body weight gain in rats, and even spermatogenesis and cisplatin-induced weight loss in other animal models (PMID 9849822, PMID 10373343, PMID 38996787, PMID 39043357). CJC-1295 combined with ipamorelin showed improved muscle tension in murine models (PMID 41476424). However, despite these encouraging results, current human trials supporting its musculoskeletal recovery or performance benefits are largely lacking or have methodological flaws (PMID 41476424, PMID 42578445).

Similarly, hexarelin has shown a wide range of protective effects in various animal and in-vitro models, including mitigating acute kidney injury, abdominal aortic aneurysm formation, acute lung injury, cardiac hypertrophy, atherosclerosis, and hydrogen peroxide-induced neuro-2A cell damage (PMID 37710348, PMID 34856183, PMID 34871336, PMID 31526442, PMID 31386895, PMID 34066741). Its direct cardiotropic actions and anti-apoptotic activity in H9c2 myocytes are also noteworthy preclinical findings (PMID 10790589). Yet, for both peptides, reviews emphasize that while preclinical studies are promising, there is a current lack of clinical trials (PMID 41490200). The majority of identified publications on these types of peptides utilize preclinical animal models, with human clinical studies being few, heterogeneous, and often without rigorous study designs or controls (PMID 42578445).

The overarching conclusion from the provided abstracts is that while therapeutic peptides, including ipamorelin and hexarelin, offer innovative options with potential to improve health and performance, further rigorous human studies are critically needed before most new peptides can be safely and widely used in humans (PMID 42123471, PMID 42021992). The claimed benefits of emerging peptide supplements for musculoskeletal recovery and performance remain unsubstantiated by current human trials (PMID 42578445). This persistent gap between preclinical promise and validated human clinical evidence represents a key challenge for both ipamorelin and hexarelin.

• Ipamorelin, the first selective growth hormone secretagogue. — European journal of endocrinology (1998). PMID 9849822
• Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. — Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews (2026). PMID 41490200
• Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. — The American journal of sports medicine (2026). PMID 41476424
• Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. — Sports medicine (Auckland, N.Z.) (2026). PMID 41966639
• Peptide Supplements and Their Therapeutic Applications in Sports Medicine. — The American journal of sports medicine (2026). PMID 42578445
• Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives. — International journal of molecular sciences (2026). PMID 42123471
• Therapeutic peptides in gerontology: mechanisms and applications for healthy aging. — Frontiers in aging (2026). PMID 42021992
• A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review. — The Journal of sports medicine and physical fitness (2026). PMID 41880199
• Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. — Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society (1999). PMID 10373343
• The influence of ghrelin agonist ipamorelin acetate on the hypothalamic-pituitary-testicular axis in a cichlid fish, Oreochromis mossambicus. — Animal reproduction science (2024). PMID 38996787
• The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism. — Physiology & behavior (2024). PMID 39043357
• Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption. — Xenobiotica; the fate of foreign compounds in biological systems (1998). PMID 9879640
• Hexarelin alleviates apoptosis on ischemic acute kidney injury via MDM2/p53 pathway. — European journal of medical research (2023). PMID 37710348
• The cardiovascular action of hexarelin. — Journal of geriatric cardiology : JGC (2014). PMID 25278975
• Hexarelin attenuates abdominal aortic aneurysm formation by inhibiting SMC phenotype switch and inflammasome activation. — Microvascular research (2022). PMID 34856183
• Hexarelin modulates lung mechanics, inflammation, and fibrosis in acute lung injury. — Drug target insights (2021). PMID 34871336
• Hexarelin protects cardiac H9C2 cells from angiotensin II-induced hypertrophy via the regulation of autophagy. — Die Pharmazie (2019). PMID 31526442
• Hexarelin attenuates atherosclerosis via inhibiting LOX-1-NF-κB signaling pathway-mediated macrophage ox-LDL uptake in ApoE-/- mice. — Peptides (2019). PMID 31386895
• Hexarelin Modulation of MAPK and PI3K/Akt Pathways in Neuro-2A Cells Inhibits Hydrogen Peroxide-Induced Apoptotic Toxicity. — Pharmaceuticals (Basel, Switzerland) (2021). PMID 34066741
• Implications of ghrelin and hexarelin in diabetes and diabetes-associated heart diseases. — Endocrine (2015). PMID 25645463
• We are ageing. — BioMed research international (2014). PMID 25045704
• Growth hormone-releasing peptides and the cardiovascular system. — Annales d'endocrinologie (2000). PMID 10790589

Both Ipamorelin and Hexarelin are supplied strictly for in-vitro and preclinical research use. They are not medicines, are not approved for human consumption in Spain, the United Kingdom, the European Union or the United States, and are not dispensed against a prescription. The research-use declaration ships with every package alongside the independent third-party COA.

Comparison pages on Peptide Intel Hub exist for laboratory-research reference. Nothing on this page constitutes a recommendation for human use of either compound.